In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteria

The in vitro activity of the new lipopeptide antibiotic LY146032 was generally four-fold greater (MIC 90 0. 5g/ml) than that of vancomycin against methicillin-susceptible or methicillin-resistantStaphybcoccus aureus and coagulase-negative species ofStaphylococcus. Enterococci,Streptococcus bovis, group B and viridans streptococci, andCorynebacterium group J-K isolates were inhibited by 4g/ml of LY146032, which represented activity equivalent to or greater than that of vancomycin. Unlike vancomycin, LY146032 was bactericidal forEnterococcus faecalis, Enterococcus faecium andListeria monocytogenes. Due to its bactericidal properties LY146032 appeared to represent an improvement over vancomycin and teicoplanin.